Advancing Therapies for Genetic Disorders

Wider Reach, Stronger Studies

Our extensive network of engaged patients assures you of access to hard-to-reach populations affected by genetic disorders. We strategically recruit the most eligible participants and increase study retention by taking biospecimen and data collection directly to the patient’s home. As a fully integrated services solution, you can expect streamlined logistics that allow you to focus on advancing the next therapy instead.

  • Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
  • Cystic Fibrosis (CF)
  • Down Syndrome (Trisomy 21)
  • Duchenne Muscular Dystrophy (DMD)
  • Glucose-6-phosphate-dehydrogenase (G6PD)
  • Hereditary Hemorrhagic Telangiectasia (HHT)
  • Hunter’s Syndrome (MPS II)
  •  Huntington's Disease (HD)
  • Myotonic Dystrophy
  • Spinal Muscular Atrophy

Sanguine's Expertise in Genetic & Rare Diseases


Patient Members


Studies Completed


Sanguine Services

  • PBMC isolation
  • "Treatment naive (eg: no disease-modifying therapies)"
  • Identify specific mutations and genotypes
  • Enzyme deficiency
  • Familial history
  • Disease Confirmation
  • Covid-19 (PCR)
  • Sickle Cell
  • HIV/HPV/Hepatitis/Herpes Etc.
  • BioMarker Quantification
  • CBC, Platelett, & Diff
  • CRP
  • Cal-Protecin
  • ANA
  • Cytokine Panel
  • BUN
  • Urinalysis
  • Thyroid Stimulating Hormone
  • Lipid Panel
  • LDH
  • Genetic Analysis
  • HLA Typing
  • dsDNA
  • RNA Vial Load Qaunitification
  • HBV Genotyping
  • Single Timepoint - Huntingtons
  • Ability to consent and enroll pediatric patients
  • Connect with hard to reach patients / rare disease patients
  • Access to patients via patient advocacy groups and non-profit organizations

Contact us to discuss your research needs

Other Services

Disease State & Healthy Leukopaks
Human PBMCs
Human Serum and Plasma
Employer Onsite Collection Programs
Lymphocyte Isolation
Noninvasive Skin Tapes
PBMCs Isolation Services for Clinical Trials
Longitudinal Sampling & Event-Based Collection

Featured Publications

Molecular Therapy - Nucleic Acids

Preclinical development of a subcutaneous ALAS1 RNAi therapeutic for treatment of hepatic porphyrias using circulating RNA quantification